Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Drotokibart, an antibody targeting IL-4Ralpha.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Betinukibart, an antibody targeting IL-17A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Afimkibart, an antibody targeting TL1A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bavituximab, an antibody targeting Phosphatidylserine.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gevokizumab, an antibody targeting IL-1beta.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ficlatuzumab, an antibody targeting HGF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Futuximab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tosatoxumab, an antibody targeting Staphylococcus aureus Toxin A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Modotuximab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dapirolizumab, an antibody targeting CD40L.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Emactuzumab, an antibody targeting CSF1R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pamrevlumab, an antibody targeting CTGF.